MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

Search

Grifols SA

Avatud

SektorRahandus

9.19 9.74

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.06

Max

9.168

Põhinäitajad

By Trading Economics

Sissetulek

17M

69M

Müük

183M

2B

P/E

Sektori keskmine

45.229

22.015

Aktsiakasum

0.101

Kasumimarginaal

3.491

Töötajad

23,833

EBITDA

57M

482M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+70.98% upside

Turustatistika

By TradingEconomics

Turukapital

3.3B

6.8B

Eelmine avamishind

-0.55

Eelmine sulgemishind

9.19

Uudiste sentiment

By Acuity

35%

65%

130 / 542 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Grifols SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. juuli 2024, 10:40 UTC

Omandamised, ülevõtmised, äriostud

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8. juuli 2024, 09:13 UTC

Omandamised, ülevõtmised, äriostud

Grifols Faces Delisting Bid From Founding Family and Brookfield

Võrdlus sarnastega

Hinnamuutus

Grifols SA Prognoos

Hinnasiht

By TipRanks

70.98% tõus

12 kuu keskmine prognoos

Keskmine 14.02 EUR  70.98%

Kõrge 19.05 EUR

Madal 11 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Grifols SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 8.574Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

130 / 542 Pingereas Rahandus

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.